Treatment with Oseltamivir in Early Suspected Cases of COVID19

Authors: Rawa Jaafar Kadhim AA*

DOI: 10.23880/mjccs-16000S1-003

Special Issue 1: Advance Studies of COVID-19

Abstract

Oseltamivir (Tamiflu), a neuraminidase inhibitor, an antiviral medication. Although of its effectiveness, still the fear of Tamiflu resistance is concerning. Tamiflu is available in limited pharmacies with an expensive price. It is available in hospitals for influenza after throat swab confirmation. Tamiflu is given as trials to give prophylaxis to COVID19 as there is no resistance to it yet in Iraq due to its limited use. This is a descriptive study, included 37 patients attended to Al-Dora Family Medical Centre from 1st to 31 of December. The cases ranged from 7 years old to 75 years old, presented with various symptoms included shortness of breath, fever, headache, diarrhea, malaise, chest pain, shivering, and dry cough. The study gives a conclusion that Tamiflu may have a role in prophylaxis against covid19 especially in countries with no resistance to it.

Keywords: Oseltamivir; Neuraminidase Inhibitor; Influenza; Prophylaxis; Tamiflu

View PDF